44.39 USD
-1.75 (-3.79%)
44.41 USD
+0.02 (+0.05%)
We assign a fundamental rating of 3 out of 10 to SLNO. SLNO was compared to 530 industry peers in the Biotechnology industry. The financial health of SLNO is average, but there are quite some concerns on its profitability. SLNO has a valuation in line with the averages, but on the other hand it scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year SLNO has reported negative net income.
SLNO had a negative operating cash flow in the past year.
In the past 5 years SLNO always reported negative net income.
SLNO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of -13.08%, SLNO belongs to the best of the industry, outperforming 81.89% of the companies in the same industry.
SLNO has a Return On Equity of -15.85%. This is amongst the best in the industry. SLNO outperforms 85.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.08% | ||
| ROE | -15.85% | ||
| ROIC | N/A |
ROA(3y)-55.18%
ROA(5y)-58.08%
ROE(3y)-109.68%
ROE(5y)-111.38%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for SLNO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for SLNO has been increased compared to 1 year ago.
Compared to 5 years ago, SLNO has more shares outstanding
The debt/assets ratio for SLNO is higher compared to a year ago.
2.2 Solvency
SLNO has an Altman-Z score of 13.72. This indicates that SLNO is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 13.72, SLNO belongs to the top of the industry, outperforming 85.85% of the companies in the same industry.
SLNO has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.10, SLNO is doing worse than 62.45% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 13.72 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
SLNO has a Current Ratio of 16.08. This indicates that SLNO is financially healthy and has no problem in meeting its short term obligations.
SLNO has a Current ratio of 16.08. This is amongst the best in the industry. SLNO outperforms 92.83% of its industry peers.
SLNO has a Quick Ratio of 15.88. This indicates that SLNO is financially healthy and has no problem in meeting its short term obligations.
SLNO has a Quick ratio of 15.88. This is amongst the best in the industry. SLNO outperforms 92.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 16.08 | ||
| Quick Ratio | 15.88 |
3. Growth
3.1 Past
SLNO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.58%, which is quite impressive.
EPS 1Y (TTM)44.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%125.68%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, SLNO will show a very strong growth in Earnings Per Share. The EPS will grow by 53.58% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y98.4%
EPS Next 2Y70.29%
EPS Next 3Y53.58%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
SLNO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 11.58 indicates a reasonable valuation of SLNO.
Based on the Price/Forward Earnings ratio, SLNO is valued cheaply inside the industry as 97.36% of the companies are valued more expensively.
SLNO is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.57, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 11.58 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
SLNO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as SLNO's earnings are expected to grow with 53.58% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y70.29%
EPS Next 3Y53.58%
5. Dividend
5.1 Amount
SLNO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
44.39
-1.75 (-3.79%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners124.99%
Inst Owner Change0%
Ins Owners1.26%
Ins Owner Change-2.9%
Market Cap2.38B
Revenue(TTM)98.67M
Net Income(TTM)-78.45M
Analysts86.32
Price Target115.81 (160.89%)
Short Float %17.56%
Short Ratio5.18
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)419.9%
Min EPS beat(2)80.77%
Max EPS beat(2)759.03%
EPS beat(4)2
Avg EPS beat(4)207.86%
Min EPS beat(4)-7.96%
Max EPS beat(4)759.03%
EPS beat(8)3
Avg EPS beat(8)72.02%
EPS beat(12)5
Avg EPS beat(12)44.04%
EPS beat(16)8
Avg EPS beat(16)37.6%
Revenue beat(2)2
Avg Revenue beat(2)30.96%
Min Revenue beat(2)27.34%
Max Revenue beat(2)34.57%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.75%
PT rev (3m)-4.37%
EPS NQ rev (1m)0.55%
EPS NQ rev (3m)175.1%
EPS NY rev (1m)50.82%
EPS NY rev (3m)91.69%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)32.63%
Revenue NY rev (1m)0%
Revenue NY rev (3m)27.95%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 11.58 | ||
| P/S | 24.16 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 4.82 | ||
| P/tB | 4.87 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.84
EYN/A
EPS(NY)3.83
Fwd EY8.63%
FCF(TTM)-0.48
FCFYN/A
OCF(TTM)-0.48
OCFYN/A
SpS1.84
BVpS9.21
TBVpS9.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.08% | ||
| ROE | -15.85% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-55.18%
ROA(5y)-58.08%
ROE(3y)-109.68%
ROE(5y)-111.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.16
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 1.14% | ||
| Cap/Sales | 0.02% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 16.08 | ||
| Quick Ratio | 15.88 | ||
| Altman-Z | 13.72 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)3.83%
Cap/Depr(5y)2.6%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%125.68%
EPS Next Y98.4%
EPS Next 2Y70.29%
EPS Next 3Y53.58%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y37.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year105.97%
EBIT Next 3Y70.33%
EBIT Next 5YN/A
FCF growth 1Y-9.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-8.95%
OCF growth 3YN/A
OCF growth 5YN/A
SOLENO THERAPEUTICS INC / SLNO FAQ
What is the ChartMill fundamental rating of SOLENO THERAPEUTICS INC (SLNO) stock?
ChartMill assigns a fundamental rating of 3 / 10 to SLNO.
Can you provide the valuation status for SOLENO THERAPEUTICS INC?
ChartMill assigns a valuation rating of 4 / 10 to SOLENO THERAPEUTICS INC (SLNO). This can be considered as Fairly Valued.
How profitable is SOLENO THERAPEUTICS INC (SLNO) stock?
SOLENO THERAPEUTICS INC (SLNO) has a profitability rating of 2 / 10.
Can you provide the financial health for SLNO stock?
The financial health rating of SOLENO THERAPEUTICS INC (SLNO) is 5 / 10.